Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic
hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B
cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse
and improving survival, while also minimizing treatment-related morbidity/ mortality and late
effects. The conditioning regimens will be dependent on the patient's minimal residual
disease (MRD) status prior to HCT using high throughput sequencing.